EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resveratrol Attenuates Gemcitabine Resistance in Hepatocellular Carcinoma Cells by Inhibiting Thymidylate Synthase

You Tang, Chuang Peng, Sulai Liu, Yunfeng Li, Siwei Zhu, Ya Zhu, Zhiguo Tan, Xu Chen, Ou Li

Frontiers in Bioscience-Landmark · 2026

DOI: 10.31083/fbl52448 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von You Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, H…. Hauptthemen laut MEDLINE: Resveratrol, Thymidylate Synthase, Drug Resistance, Neoplasm, Carcinoma, Hepatocellular. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Natural Science Foundation, Leading talent project of Hunan Provincial People's Hospital, Scientific and Technological Innovation Team Project of Hunan Provincial People's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background:Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Gemcitabine (Gem) is a commonly used drug against HCC, but its efficacy is limited by the development of resistance. Resveratrol (Res), a natural polyphenol with antitumor activity, may reverse Gem resistance in HCC, although the mechanism remains unclear.Methods:The effects of Res on the proliferation, apoptosis, cell cycle, and invasion of Hep3B and HuH-7 cells were assessed via cell counting kit-8 (CCK-8), clonogenic, flow cytometry, and Transwell assays, respectively. Potential Res targets were predicted by network pharmacology, and markers of HCC prognosis were identified from the cancer genome atlas (TCGA) data. The interaction between Res and thymidylate synthase (TYMS) was validated by molecular docking and dynamics simulation. A Gem-resistant HuH-7 cell line (HuH-7/GR) was established, and when these cells were treated with Res combined with Gem, the effect on Gem sensitivity was detected by CCK-8 assay, clonogenic assay, and flow cytometry. Finally, a subcutaneous nude mouse model of HCC was used to evaluate the in vivo effects of Res combined with Gem.Results:Res inhibited HCC cell proliferation, induced apoptosis and G2/M arrest, and suppressed invasion in a concentration-dependent manner. Network pharmacology and TCGA analysis identified TYMS as an important target gene for Res. TYMS was highly expressed in HCC tissues and correlated with poor prognosis. Res treatment reduced TYMS expression, while molecular docking and simulation showed stable binding of Res to TYMS. TYMS levels were elevated in HuH-7/GR resistant cells. Res combined with Gem was found to reverse drug resistance, inhibit proliferation and colony formation, and induce apoptosis. The Res + Gem combination group showed the smallest tumor volume in the in vivo model.Conclusion:By attenuating Gem resistance through TYMS inhibition, Res holds promise as a clinically viable adjunct to Gem-based chemotherapy, offering a potential strategy to improve outcomes in HCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ResveratrolThymidylate SynthaseDrug Resistance, NeoplasmCarcinoma, HepatocellularDeoxycytidineLiver NeoplasmsHumansGemcitabineAnimalsMiceApoptosisCell ProliferationCell Line, TumorXenograft Model Antitumor AssaysMice, NudeMolecular Docking SimulationAntimetabolites, Antineoplastic

Stichwörter der Autor:innen

drug resistancegemcitabinehepatocellular carcinomaresveratrolthymidylate synthase

Substanzen

ResveratrolThymidylate SynthaseDeoxycytidineGemcitabineTYMS protein, humanAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China.
  • Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, 650000 Kunming, Yunnan, China.
  • The First School of Clinical Medicine, Lanzhou University, 730000 Lanzhou, Gansu, China.

Förderung

  • Hunan Provincial Natural Science Foundation
  • Leading talent project of Hunan Provincial People's Hospital
  • Scientific and Technological Innovation Team Project of Hunan Provincial People's Hospital
  • Leading talent project of Hunan Provincial People’s Hospital
  • Scientific and Technological Innovation Team Project of Hunan Provincial People’s Hospital

Zitieren

APA

Tang, Y., Peng, C., Liu, S., Li, Y., Zhu, S., Zhu, Y., Tan, Z., Chen, X., & Li, O. (2026). Resveratrol Attenuates Gemcitabine Resistance in Hepatocellular Carcinoma Cells by Inhibiting Thymidylate Synthase. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl52448

Vancouver

Tang Y, Peng C, Liu S, Li Y, Zhu S, Zhu Y, et al. Resveratrol Attenuates Gemcitabine Resistance in Hepatocellular Carcinoma Cells by Inhibiting Thymidylate Synthase. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl52448

BibTeX
@article{Tang2026,
  author = {Tang, You and Peng, Chuang and Liu, Sulai and Li, Yunfeng and Zhu, Siwei and Zhu, Ya and Tan, Zhiguo and Chen, Xu and Li, Ou},
  title = {Resveratrol Attenuates Gemcitabine Resistance in Hepatocellular Carcinoma Cells by Inhibiting Thymidylate Synthase},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  doi = {10.31083/fbl52448}
}
Kostenlos starten →